Document and Entity Information
Document and Entity Information | Nov. 03, 2023 |
Cover [Abstract] | |
Security Exchange Name | NASDAQ |
Amendment Flag | true |
Entity Central Index Key | 0001501756 |
Document Type | 8-K/A |
Document Period End Date | Nov. 03, 2023 |
Entity Registrant Name | Adverum Biotechnologies, Inc. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-36579 |
Entity Tax Identification Number | 20-5258327 |
Entity Address, Address Line One | 100 Cardinal Way |
Entity Address, City or Town | Redwood City |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94063 |
City Area Code | (650) |
Local Phone Number | 656-9323 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock |
Trading Symbol | ADVM |
Entity Emerging Growth Company | false |
Amendment Description | The Company is filing this Form 8-K/A to amend its Form 8-K filed with the Securities and Exchange Commission on November 6, 2023 to disclose that upon the recommendation of the Nominating and Corporate Governance Committee of the Board made on November 28, 2023, the Board appointed Dr. Nicholson to serve as a member of the Research and Development Committee. |